The Trump administration recently announced a plan to begin setting pricing targets for medicines in a “most favored nation” policy, which aims to tie U.S. drug prices to the lowest possible price among other high-income countries. Of course, paying less for drugs seems like a good idea. In any market, including medicines, paying less often means getting […]
Author Archives: Kirsten Axelsen
Kirsten Axelsen is a consultant and policy adviser to biopharmaceutical companies and is a non-resident fellow with the American Enterprise Institute. She wrote this for InsideSources.com.